$HRMY
Harmony Biosciences Holdings Inc Stock $hrmy

$hrmy Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000155837024006203 Filed on April 30, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$172.8M	$154.6M	$119.1M
YoY Change	28.76%	29.79%	39.63%
Cost Of Revenue	$32.14M	$27.48M	$20.78M
YoY Change	28.53%	32.26%	41.21%
Gross Profit	$140.7M	$127.1M	$98.35M
YoY Change	28.81%	29.27%	39.31%
Gross Profit Margin	81.4%	82.22%	82.56%
Selling, General & Admin	$55.73M	$52.91M	$44.63M
YoY Change	17.73%	18.54%	25.86%
% of Gross Profit	39.62%	41.62%	45.38%
Research & Development	$63.58M	$22.19M	$13.29M
YoY Change	324.76%	66.97%	75.36%
% of Gross Profit	45.2%	17.45%	13.51%
Depreciation & Amortization	$6.052M	$163.0K	$103.0K
YoY Change	-0.2%	58.25%	-11.97%
% of Gross Profit	4.3%	0.13%	0.1%
Operating Expenses	$119.3M	$75.10M	$57.92M
YoY Change	91.5%	29.65%	34.58%
Operating Profit	$21.36M	$52.03M	$40.42M
YoY Change	-54.47%	28.72%	46.69%
Interest Expense	$301.0K	$4.535M	-$2.645M
YoY Change	-110.84%	-271.46%	-36.56%
% of Operating Profit	1.41%	8.72%	-6.54%
Other Income/Expense, Net	$37.00K	-$141.0K	$2.000K
YoY Change	-219.35%	-7150.0%	-200.0%
Pretax Income	$21.69M	$51.79M	$37.78M
YoY Change	-50.8%	37.07%	61.56%
Income Tax	$10.10M	$13.45M	$8.295M
% Of Pretax Income	46.57%	25.97%	21.96%
Net Earnings	$11.59M	$38.33M	$29.49M
YoY Change	-66.21%	30.01%	37.24%
Net Earnings / Revenue	6.71%	24.79%	24.75%
Basic Earnings Per Share	$0.20	$0.68	$0.49
Diluted Earnings Per Share	$0.20	$0.67	$0.48
COMMON SHARES
Basic Shares Outstanding	56.79M	56.77M	59.62M
Diluted Shares Outstanding	57.54M	57.60M	61.22M

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$346.9M	$372.4M	$343.9M
YoY Change	-6.49%	8.28%	53.18%
Cash & Equivalents	$317.3M	$333.0M	$288.0M
Short-Term Investments	$29.61M	$39.37M	$55.92M
Other Short-Term Assets	$6.507M	$8.683M	$6.145M
YoY Change	-59.31%	41.3%	80.21%
Inventory	$5.643M	$5.857M	$4.090M
Prepaid Expenses	$16.13M	$12.89M	$11.40M
Receivables	$83.16M	$79.72M	$52.58M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$458.3M	$479.5M	$418.1M
YoY Change	0.59%	14.69%	49.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$754.0K	$213.0K	$470.0K
YoY Change	-71.32%	-54.68%	-37.17%
Goodwill
YoY Change
Intangibles	$125.2M	$131.1M	$155.0M
YoY Change	-16.0%	-15.38%	-13.33%
Long-Term Investments	$87.18M	$81.24M	$48.54M
YoY Change	48.64%	67.38%
Other Assets	$6.465M	$6.969M	$2.870M
YoY Change	-93.14%	142.82%	-15.91%
Total Long-Term Assets	$400.0M	$367.5M	$297.0M
YoY Change	31.36%	23.73%	61.64%
TOTAL ASSETS
Total Short-Term Assets	$458.3M	$479.5M	$418.1M
Total Long-Term Assets	$400.0M	$367.5M	$297.0M
Total Assets	$858.4M	$847.0M	$715.1M
YoY Change	12.92%	18.44%	54.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$22.68M	$15.14M	$6.414M
YoY Change	245.62%	136.11%	-7.1%
Accrued Expenses	$91.64M	$91.70M	$56.81M
YoY Change	24.99%	61.41%	44.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$15.00M	$15.00M	$6.500M
YoY Change	36.36%	130.77%	225.0%
Total Short-Term Liabilities	$146.6M	$154.3M	$85.36M
YoY Change	57.54%	80.7%	51.01%
LONG-TERM LIABILITIES
Long-Term Debt	$171.4M	$175.0M	$185.1M
YoY Change	-5.02%	-5.44%	-2.55%
Other Long-Term Liabilities	$1.796M	$2.342M	$1.625M
YoY Change	21.43%	44.12%	-47.21%
Total Long-Term Liabilities	$173.2M	$177.3M	$186.7M
YoY Change	-4.81%	-5.01%	-3.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$146.6M	$154.3M	$85.36M
Total Long-Term Liabilities	$173.2M	$177.3M	$186.7M
Total Liabilities	$319.8M	$331.6M	$272.1M
YoY Change	16.29%	21.89%	9.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.35M	-$104.9M	-$242.6M
YoY Change	-55.19%	-56.75%	-43.85%
Common Stock	$632.2M	$620.5M	$685.7M
YoY Change	-8.91%	-9.51%	6.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$538.6M	$515.4M	$443.0M
YoY Change
Total Liabilities & Shareholders Equity	$858.4M	$847.0M	$715.1M
YoY Change	12.92%	18.44%	54.11%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$11.59M	$38.33M	$29.49M
YoY Change	-66.21%	30.01%	37.24%
Depreciation, Depletion And Amortization	$6.052M	$163.0K	$103.0K
YoY Change	-0.2%	58.25%	-11.97%
Cash From Operating Activities	$42.62M	$31.14M	$42.56M
YoY Change	14.99%	-26.83%	47.51%
INVESTING ACTIVITIES
Capital Expenditures	$632.0K	$5.000K	$0.00
YoY Change	208.29%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$54.22M	-$6.181M	-$1.790M
YoY Change	616.68%	245.31%
Cash From Investing Activities	-$54.86M	-$6.186M	-$1.790M
YoY Change	605.91%	245.59%	-95.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$3.750M	$500.0K
YoY Change		650.0%	0.0%
Cash From Financing Activities	-3.446M	-3.634M	3.409M
YoY Change	916.52%	-206.6%	146.49%
NET CHANGE
Cash From Operating Activities	42.62M	31.14M	42.56M
Cash From Investing Activities	-54.86M	-6.186M	-1.790M
Cash From Financing Activities	-3.446M	-3.634M	3.409M
Net Change In Cash	-15.69M	21.32M	44.18M
YoY Change	-154.17%	-51.74%	-550.34%
FREE CASH FLOW
Cash From Operating Activities	$42.62M	$31.14M	$42.56M
Capital Expenditures	$632.0K	$5.000K	$0.00
Free Cash Flow	$41.99M	$31.14M	$42.56M
YoY Change	13.91%	-26.84%	47.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001802665
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2024Q1	us-gaap	Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2024Q1	us-gaap	Other Liabilities OtherLiabilities	0
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	0
CY2024Q1	us-gaap	Other Liability Related Party Type Extensible Enumeration OtherLiabilityRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Other Liability Related Party Type Extensible Enumeration OtherLiabilityRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-39450
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	HARMONY BIOSCIENCES HOLDINGS, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2279923
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	630 W.
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Germantown Pike
CY2024Q1	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 215
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Plymouth Meeting
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19462
CY2024Q1	dei	City Area Code CityAreaCode	484
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	539-9800
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 value per share
CY2024Q1	dei	Trading Symbol TradingSymbol	HRMY
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56791861
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	332981000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	311660000
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	39369000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	41800000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	79719000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	74140000
CY2024Q1	us-gaap	Inventory Net InventoryNet	5857000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5363000
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12894000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12570000
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	8683000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5537000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	479503000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	451070000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	213000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	371000
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	270000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	270000
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	81244000
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	72169000
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	131147000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	137108000
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	147639000
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	144162000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6969000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6298000
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	367482000
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	360378000
CY2024Q1	us-gaap	Assets Assets	846985000
CY2023Q4	us-gaap	Assets Assets	811448000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	15144000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17730000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7317000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23747000
CY2024Q1	hrmy	Accrued Liabilities Other Than Accrued Compensation Current AccruedLiabilitiesOtherThanAccruedCompensationCurrent	91699000
CY2023Q4	hrmy	Accrued Liabilities Other Than Accrued Compensation Current AccruedLiabilitiesOtherThanAccruedCompensationCurrent	99494000
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	15000000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	15000000
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	25093000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7810000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	154253000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	163781000
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	174996000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	178566000
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2342000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2109000
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	177338000
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	180675000
CY2024Q1	us-gaap	Liabilities Liabilities	331591000
CY2023Q4	us-gaap	Liabilities Liabilities	344456000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56791214
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56791214
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56769081
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56769081
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	620507000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	610266000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-171000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-173000
CY2024Q1	hrmy	Stock Issued During Period Value Stock Options And Restricted Stock Units Exercised StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised	-153000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10394000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	515394000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104943000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143277000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	515394000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	466992000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	846985000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	811448000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	154615000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119126000
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	27484000
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	20780000
CY2024Q1	us-gaap	Gross Profit GrossProfit	127131000
CY2023Q1	us-gaap	Gross Profit GrossProfit	98346000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22189000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13289000
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	27233000
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	22572000
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25676000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22062000
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	75098000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	57923000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	52033000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	40423000
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-141000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000
CY2024Q1	us-gaap	Interest Expense InterestExpense	4535000
CY2023Q1	us-gaap	Interest Expense InterestExpense	5731000
CY2024Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	4428000
CY2023Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3086000
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	51785000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	37780000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13451000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8295000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	38334000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	29485000
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-173000
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	120000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	38161000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	29605000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.68
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.49
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.67
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.48
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56771251
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59732157
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57597627
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61221511
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	466992000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	38334000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	402838000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	29485000
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	120000
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3395000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7203000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	443041000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	38334000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	29485000
CY2024Q1	us-gaap	Depreciation Depreciation	163000
CY2023Q1	us-gaap	Depreciation Depreciation	103000
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5961000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5961000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10394000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7203000
CY2024Q1	hrmy	Stock Appreciation Rights Market Adjustment StockAppreciationRightsMarketAdjustment	40000
CY2023Q1	hrmy	Stock Appreciation Rights Market Adjustment StockAppreciationRightsMarketAdjustment	-642000
CY2024Q1	hrmy	Adjustment For Amortization Of Debt Issuance Costs AdjustmentForAmortizationOfDebtIssuanceCosts	180000
CY2023Q1	hrmy	Adjustment For Amortization Of Debt Issuance Costs AdjustmentForAmortizationOfDebtIssuanceCosts	416000
CY2024Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-3477000
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-3442000
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	594000
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	636000
CY2024Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	467000
CY2023Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	369000
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5579000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2165000
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	494000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-207000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3439000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-592000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2586000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2628000
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-8229000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1850000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	31141000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	42559000
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	25106000
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	47776000
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	18925000
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	45986000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6186000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1790000
CY2024Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3750000
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	500000
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	116000
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3909000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3634000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3409000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21321000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	44178000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	311930000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	244534000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	333251000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288712000
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	4585000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	5017000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104943000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143277000
CY2024Q1	us-gaap	Investments And Cash InvestmentsAndCash	453594000
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reclassifications</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain prior period amounts within the unaudited condensed consolidated statements of operations and comprehensive income have been reclassified to conform to current period presentation. In particular, interest expense and interest income were previously classified together as interest expense, net and are now separately classified as interest expense and interest income, respectively. The reclassification of these items had no impact on net income, earnings per share or accumulated deficit in current or prior periods.</p>
CY2024Q1	hrmy	Number Of Approved Commercial Products NumberOfApprovedCommercialProducts	1
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. </p>
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	332981000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	311660000
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	270000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	270000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	333251000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	311930000
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held in five financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of March 31, 2024, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 41% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 36% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 23% of gross accounts receivable. As of December 31, 2023, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 39% of gross accounts receivable, CVS Caremark, which accounted for 32% of gross accounts receivable; and Pantherx, which accounted for 29% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2024, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 42% of gross product revenue; Accredo accounted for 33% of gross product revenue; and Pantherx accounted for 25% of gross product revenue. For the three months ended March 31, 2023, three customers accounted for 100% of gross product revenue; CVS Caremark accounted for 35% of gross product revenue; Pantherx accounted for 33% of gross product revenue; and Accredo accounted for 32% of gross product revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single supplier for its product and a single supplier for its active pharmaceutical ingredient.</p>
CY2024Q1	hrmy	Concentrations Of Risk Number Of Financial Institutions ConcentrationsOfRiskNumberOfFinancialInstitutions	5
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023Q4	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	2645000
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	384692000
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	358538000
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1009000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1060000
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1748000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2020000
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3100000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2283000
CY2024Q1	us-gaap	Inventory Net InventoryNet	5857000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5363000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5961000
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5961000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	17884000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	23845000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	23845000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	23845000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	23845000
CY2024Q1	hrmy	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	17883000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	131147000
CY2024Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	215000000
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	215000000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	83853000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	77892000
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	131147000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	137108000
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	24738000
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	40419000
CY2024Q1	hrmy	Accrued Rebates And Other Sales Deductions Current AccruedRebatesAndOtherSalesDeductionsCurrent	48165000
CY2023Q4	hrmy	Accrued Rebates And Other Sales Deductions Current AccruedRebatesAndOtherSalesDeductionsCurrent	38842000
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	3125000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3354000
CY2024Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2999000
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2354000
CY2024Q1	hrmy	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	7898000
CY2023Q4	hrmy	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	9835000
CY2024Q1	hrmy	Accrued Professional Fees Consulting And Other Services AccruedProfessionalFeesConsultingAndOtherServices	1918000
CY2023Q4	hrmy	Accrued Professional Fees Consulting And Other Services AccruedProfessionalFeesConsultingAndOtherServices	2195000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2856000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2495000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91699000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	99494000
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	192500000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	196250000
CY2024Q1	hrmy	Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing	2504000
CY2023Q4	hrmy	Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing	2684000
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	189996000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	193566000
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	15000000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	15000000
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	174996000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	178566000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	11250000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	16250000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	20000000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	20000000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	125000000
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	192500000
CY2024Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4355000
CY2023Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	5315000
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	180000
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	416000
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	4535000
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	5731000
CY2018Q2	hrmy	Operating Lease Office Space OperatingLeaseOfficeSpace	15000
CY2018Q2	hrmy	Operating Lease Additional Office Space Leased One OperatingLeaseAdditionalOfficeSpaceLeasedOne	13000
CY2018Q2	hrmy	Operating Lease Additional Office Space Leased Two OperatingLeaseAdditionalOfficeSpaceLeasedTwo	7000
CY2024Q1	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2024Q1	us-gaap	Lessee Operating Lease Existence Of Option To Terminate LesseeOperatingLeaseExistenceOfOptionToTerminate	true
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	509000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	378000
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0732
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3046000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2344000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1793000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1437000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1276000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1082000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3069000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2519000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	561000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	428000
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1198000
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	526000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1564000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1239000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	473000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3279000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	210000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3069000
CY2024Q1	hrmy	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6316422
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.47
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M1D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1071750
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	30.69
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	14120
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.22
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	11529
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	39.31
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7362523
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.25
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7260
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7260
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7487
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8078
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0406
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0420
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0342
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0462
CY2024Q1	hrmy	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount	0.0000
CY2023	hrmy	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount	0.0000
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10434000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6561000
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	38334000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	29485000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.68
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.49
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.67
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.48
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56771251
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59732157
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57597627
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61221511
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	826376
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1489354
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7281505
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4661499
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.028
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.063
CY2024Q1	hrmy	Effective Income Tax Rate Reconciliation Credits EffectiveIncomeTaxRateReconciliationCredits	-0.010
CY2023Q1	hrmy	Effective Income Tax Rate Reconciliation Credits EffectiveIncomeTaxRateReconciliationCredits	-0.029
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.004
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.004
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.005
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.260
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.220
CY2024Q1	us-gaap	Other Receivables OtherReceivables	0
CY2023Q4	us-gaap	Other Receivables OtherReceivables	0
CY2024Q1	ecd	Trd Arr Adoption Date TrdArrAdoptionDate	2024-02-23
CY2024Q1	ecd	Trd Arr Ind Name TrdArrIndName	Jeffrey Dierks
CY2024Q1	ecd	Trd Arr Ind Title TrdArrIndTitle	Chief Commercial Officer
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true
CY2024Q1	ecd	Trd Arr Securities Agg Avail Amt TrdArrSecuritiesAggAvailAmt	35708
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001558370-24-006203-index-headers.html	Edgar Link	pending
0001558370-24-006203-index.html	Edgar Link	pending
0001558370-24-006203.txt	Edgar Link	pending
0001558370-24-006203-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hrmy-20240331.xsd	Edgar Link	pending
hrmy-20240331x10q.htm	Edgar Link	pending
hrmy-20240331xex10d1.htm	Edgar Link	pending
hrmy-20240331xex10d2.htm	Edgar Link	pending
hrmy-20240331xex31d1.htm	Edgar Link	pending
hrmy-20240331xex31d2.htm	Edgar Link	pending
hrmy-20240331xex32d1.htm	Edgar Link	pending
hrmy-20240331xex32d2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hrmy-20240331_cal.xml	Edgar Link	unprocessable
hrmy-20240331_def.xml	Edgar Link	unprocessable
hrmy-20240331_lab.xml	Edgar Link	unprocessable
hrmy-20240331_pre.xml	Edgar Link	unprocessable
hrmy-20240331x10q_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HRMY
Harmony Biosciences Holdings Inc Stock $hrmy

2024 Q2 Form 10-Q Financial Statement

#000155837024006203 Filed on April 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRMY Harmony Biosciences Holdings Inc Stock $hrmy

2024 Q2 Form 10-Q Financial Statement

#000155837024006203 Filed on April 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRMY
Harmony Biosciences Holdings Inc Stock $hrmy